Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
BioPharma Drive: Drug Pricing
JUNE 21, 2024
A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.
Let's personalize your content